Bionomics (NASDAQ:BNOX – Get Free Report) and Aeglea BioTherapeutics (NASDAQ:AGLE – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.
Risk and Volatility
Bionomics has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Aeglea BioTherapeutics has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500.
Profitability
This table compares Bionomics and Aeglea BioTherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bionomics | N/A | N/A | N/A |
| Aeglea BioTherapeutics | -6,678.20% | -132.05% | -96.69% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bionomics | 0 | 1 | 3 | 0 | 2.75 |
| Aeglea BioTherapeutics | 0 | 4 | 1 | 0 | 2.20 |
Bionomics presently has a consensus target price of $10.33, indicating a potential upside of 303.13%. Aeglea BioTherapeutics has a consensus target price of $1.88, indicating a potential upside of 216.08%. Given Bionomics’ stronger consensus rating and higher possible upside, research analysts plainly believe Bionomics is more favorable than Aeglea BioTherapeutics.
Insider and Institutional Ownership
3.2% of Bionomics shares are owned by institutional investors. Comparatively, 63.2% of Aeglea BioTherapeutics shares are owned by institutional investors. 1.5% of Bionomics shares are owned by company insiders. Comparatively, 3.2% of Aeglea BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Bionomics and Aeglea BioTherapeutics’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bionomics | $263,634.00 | 79.34 | -$15.79 million | N/A | N/A |
| Aeglea BioTherapeutics | $1.17 million | 33.30 | -$83.82 million | ($0.84) | -0.71 |
Bionomics has higher earnings, but lower revenue than Aeglea BioTherapeutics.
Summary
Bionomics beats Aeglea BioTherapeutics on 8 of the 12 factors compared between the two stocks.
About Bionomics
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.
